They jumped to call the biotech sector a bubble, accentuating its volatility. Instead of saying WOW about Gilead’s (GILD) 3.49 billion net income, calculated as $2.18 a share, they called for a selloff of the stock. The 3.49 billion net income and $2.18 income a share are compared with $791 million, or 47 cents a share, a year earlier. This is big for us, but …

Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Today’s news is good for Agenus (AGEN) whom we kept in our portfolio because of many reasons – all have been mentioned in our previous articles. What makes today’s news about the collaboration between Incyte (INCY) and Agenus (AGEN) more exciting is that it was not the first that demonstrate the firm is on …